Home > Qtrly Results > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Quarterly Results Analysis [Sep2024]

GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Best Quarterly Growth Mid Cap Stocks
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results

GLENMARK PHARMACEUTICALS Quarterly Results

Consolidated Sep2024
UnAudited
Jun2024
UnAudited
Mar2024
UnAudited
Dec2023
UnAudited
Sep2023
Audited
Jun2023
UnAudited
Mar2023
Audited
Dec2022
UnAudited
Revenues ₹3,434 Cr ₹3,244 Cr ₹3,063 Cr ₹2,507 Cr ₹3,207 Cr ₹3,036 Cr ₹3,001 Cr ₹3,100 Cr
Expenses ₹2,832 Cr ₹2,656 Cr ₹2,559 Cr ₹2,715 Cr ₹2,745 Cr ₹2,599 Cr ₹2,603 Cr ₹2,626 Cr
Operating Income ₹602 Cr ₹588 Cr ₹504 Cr ₹-209 Cr ₹462 Cr ₹437 Cr ₹398 Cr ₹474 Cr
Other Income ₹39 Cr ₹31 Cr ₹773 Cr ₹45 Cr ₹2 Cr ₹20 Cr ₹-42 Cr ₹71 Cr
Interest ₹48 Cr ₹40 Cr ₹149 Cr ₹134 Cr ₹121 Cr ₹112 Cr ₹109 Cr ₹97 Cr
Depreciation ₹120 Cr ₹118 Cr ₹151 Cr ₹147 Cr ₹141 Cr ₹142 Cr ₹135 Cr ₹152 Cr
Profit Before Tax ₹473 Cr ₹462 Cr ₹531 Cr ₹-521 Cr ₹-124 Cr ₹151 Cr ₹-688 Cr ₹330 Cr
Profit After Tax ₹354 Cr ₹340 Cr ₹-1,239 Cr ₹-450 Cr ₹-180 Cr ₹38 Cr ₹-549 Cr ₹186 Cr
EPS ₹12.55 ₹12.06 ₹-43.17 ₹-12.45 ₹-2.90 ₹5.31 ₹-15.18 ₹9.66
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS -6.9% -0.2% 70.3%
SUN PHARMACEUTICAL INDUSTRIES -3.7% -2.5% 31.9%
CIPLA -3.2% 0% 8.2%
DR REDDYS LABORATORIES -2.4% 7.3% 15.3%
ZYDUS LIFESCIENCES 2% 2.3% 37.9%
DIVIS LABORATORIES 2.3% 2.1% 46.9%
MANKIND PHARMA -7.1% 1.2% 20.5%
TORRENT PHARMACEUTICALS -2.1% -2.8% 37.8%
LUPIN -4.3% 3.8% 53.3%

GLENMARK PHARMACEUTICALS Quarterly Revenues

Revenues
Q-o-Q

5.84 %

Y-o-Y

7.06 %

Quarters Revenues % Change
Sep2024 ₹3,434 Cr
5.84
Jun2024 ₹3,244 Cr
5.92
Mar2024 ₹3,063 Cr
22.19
Dec2023 ₹2,507 Cr
-21.85
Sep2023 ₹3,207 Cr
5.64
Jun2023 ₹3,036 Cr
1.18
Mar2023 ₹3,001 Cr
-3.21
Dec2022 ₹3,100 Cr -

GLENMARK PHARMACEUTICALS Quarterly Operating Profit

Operating Profit
Q-o-Q

2.33 %

Y-o-Y

30.20 %

Quarters Operating Profit % Change
Sep2024 ₹602 Cr
2.33
Jun2024 ₹588 Cr
16.63
Mar2024 ₹504 Cr
Positive
Dec2023 ₹-209 Cr
Negative
Sep2023 ₹462 Cr
5.70
Jun2023 ₹437 Cr
9.91
Mar2023 ₹398 Cr
-16.06
Dec2022 ₹474 Cr -
Operating Margins
Q-o-Q

-3.31 %

Y-o-Y

21.65 %

Quarters Operating Margin% % Change
Sep2024 17.53%
-3.31
Jun2024 18.13%
10.08
Mar2024 16.47%
Positive
Dec2023 -8.32%
Negative
Sep2023 14.41%
0.00
Jun2023 14.41%
8.67
Mar2023 13.26%
-13.28
Dec2022 15.29% -

GLENMARK PHARMACEUTICALS Quarterly Profit After Tax

Profit After Tax(PAT)
Q-o-Q

4.19 %

Y-o-Y

Positive

Quarters Profit After Tax % Change
Sep2024 ₹354 Cr
4.19
Jun2024 ₹340 Cr
Positive
Mar2024 ₹-1,239 Cr
Negative
Dec2023 ₹-450 Cr
Negative
Sep2023 ₹-180 Cr
Negative
Jun2023 ₹38 Cr
Positive
Mar2023 ₹-549 Cr
Negative
Dec2022 ₹186 Cr -
PAT Margins
Q-o-Q

-1.62 %

Y-o-Y

Positive

Quarters PAT Margin(%) % Change
Sep2024 10.32 %
-1.62
Jun2024 10.49 %
Positive
Mar2024 -40.44 %
Negative
Dec2023 -17.94 %
Negative
Sep2023 -5.62 %
Negative
Jun2023 1.24 %
Positive
Mar2023 -18.31 %
Negative
Dec2022 5.99 % -

GLENMARK PHARMACEUTICALS Quarterly Earnings Per Share (EPS)

EPS
Q-o-Q

4.06 %

Y-o-Y

Positive

Quarters EPS % Change
Sep2024 ₹12.55
4.06
Jun2024 ₹12.06
Positive
Mar2024 ₹-43.17
Negative
Dec2023 ₹-12.45
Negative
Sep2023 ₹-2.9
Negative
Jun2023 ₹5.31
Positive
Mar2023 ₹-15.18
Negative
Dec2022 ₹9.66 -

You may also like the below Video Courses